Acne News and Research

Latest Acne News and Research

PhotoMedex fourth quarter revenues increase 26% to $28.8M

PhotoMedex, Inc. today reported financial results for the three and 12 months ended December 31, 2011.

9 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

Heborium first quarter sales increase 23%

Herborium Group, Inc., is pleased to announce today that the Company' Internet sales for first quarter of 2012 grew 23% in comparison to the same quarter of 2011.

8 Mar 2012

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the initiation of two pivotal U.S. Phase III trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental (under the chin) fat.

5 Mar 2012

Birmingham dermatologist first to offer anti-cellulite Cellulaze procedure

Dr. Barry Ginsburg, a Birmingham, AL based Dermatologist today announced his practice is the first in the state to offer the Cellulaze by Cynosure, the world's first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market.

20 Feb 2012

Watson seeks FDA approval to market generic Beyaz

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg.

13 Feb 2012

New skin fillers and laser technologies can correct signs of aging

As we age, our skin undergoes a number of changes affecting its texture, volume and appearance. Fortunately, dermatologists can use fillers or lasers to correct the most notable signs of aging and can recommend skin care products with added ingredients that can further repair damaged skin.

8 Feb 2012

Mylan acquires two dermatological drugs from Valeant

Mylan Inc. today announced that it has successfully completed the acquisition of two dermatological products from Valeant Pharmaceuticals.

6 Feb 2012

Watson introduces new oral contraceptive, Vestura

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product.

18 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

Study identifies tertiary treatment as an important source of antibiotic resistant genes

Water discharged into lakes and rivers from municipal sewage treatment plants may contain significant concentrations of the genes that make bacteria antibiotic-resistant. That's the conclusion of a new study on a sewage treatment plant on Lake Superior in the Duluth, Minn., harbor that appears in ACS' journal Environmental Science & Technology.

8 Dec 2011

Notch inhibitor appears to treat breast cancer

In a novel therapeutic approach to treating breast cancer, Loyola University Medical Center researchers are reporting positive results from a clinical trial of a drug that targets tumor stem cells.

8 Dec 2011

FDA approves Watson's ANDA for generic Yaz oral contraceptive

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz oral contraceptive product.

29 Nov 2011

Avita Medical announces acquisition of intellectual property from McComb Foundation

Avita Medical Ltd., the regenerative medicine company, is pleased to announce that it has successfully completed the transfer and acquisition of intellectual property currently licensed through the McComb Foundation of Western Australia.

29 Nov 2011

Sore throat among young adults taking antibiotics for acne: Study

A new study reveals that young adults who take oral antibiotics for acne may be more likely to get sore throats. The reason behind this is unclear say researchers. However they add that long-term use of antibiotics might change the balance of bacteria in the throat. In principle, that could allow infection-causing strains to multiply.

22 Nov 2011

Obagi Medical Products third quarter net income increases to $4.4M

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today reported financial results for the third quarter and nine months ended September 30, 2011.

10 Nov 2011

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

7 Nov 2011

Helix Biomedix third quarter revenue increases 321% to $395,000

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the company's third quarter ended September 30, 2011.

5 Nov 2011

Internet-based communication improves teenagers' use of topical acne therapy

Tech-savvy teens with acne used their medicine more frequently when they also took part in a web-based survey, a new study from Wake Forest Baptist Medical Center finds.

1 Nov 2011